TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06130657

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Maxillary Sinus Floor Elevation using surgical guide
Description: The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Maxillary Sinus Floor Elevation without surgical guide
Description: The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
Study: NCT03184909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocimum Sanctum
Description: Active capsules containing leaves of organically prepared ocimum sanctum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules of look alike inert substance for control
Study: NCT02687594

Intervention type: DRUG
Intervention: sucroferric oxyhydroxide
Description: The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
Study: NCT02930655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Description: All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Description: All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
Study: NCT03960138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-burst stimulation (iTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-burst stimulation (iTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta-burst stimulation (cTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta-burst stimulation (cTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
Study: NCT03599141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-building Self-management Together
Description: Trust building plus depression self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression Management
Description: Traditional depression self-management
Study: NCT02274584

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR T cells
Description: Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
Study: NCT03016442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Double Balloon Catheter
Description: A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: 10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Study: NCT02226042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
Study: NCT00634244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study: NCT02636348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Description: 2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Description: 2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
Study: NCT03639935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib 600 mg PO BID days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV days 1 and 15
Study: NCT02636348

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered daily as 8 placebo pills or 2 unfortified snack bars.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered daily as 8 placebo pills or 2 unfortified snack bars.
Study: NCT00465153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flax oil containing alpha linolenic acid
Description: 14g alpha linolenic acid per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: flax oil containing alpha linolenic acid
Description: 14g alpha linolenic acid per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Resistance training
Study: NCT04491786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin plus nefopam
Study: NCT00466999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: single dose of 400 mcg misoprostol administered sublingually
Study: NCT03223675

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hippocampal-sparing WBRT
Study: NCT04438824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
Study: NCT04587492

Intervention type: DRUG
Intervention: Nusinersen
Description: Treatment with nusinersen
Study: NCT04063202

Intervention type: OTHER
Intervention: Observation
Description: The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
Study: NCT04053387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapinarof cream, 1%
Description: Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
Study: NCT00694863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracosactide hexacetaat
Description: Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
Study: NCT00466999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: standard surgical treatment (dilation and curettage or manual vacuum aspiration)
Study: NCT01721408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/cilastatin
Description: every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
Study: NCT04065880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil®
Description: topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoveil®
Description: bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
Study: NCT02510729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Study: NCT04565249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04813393

Intervention type: OTHER
Intervention: Questionnaire Development
Description: To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
Study: NCT02271048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ultrasonography interpretation using the smartphone
Description: The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ultrasonography interpretation using the smartphone
Description: The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
Study: NCT00633412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150mg oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral tablet daily
Study: NCT01061229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic drug C12
Description: Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
Study: NCT06630481

Intervention type: DRUG
Intervention: neoadjuvant therapy
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.

Intervention type: DRUG
Intervention: neoadjuvant therapy
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.

Intervention type: DRUG
Intervention: neoadjuvant therapy
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.

Intervention type: DRUG
Intervention: neoadjuvant therapy
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.

Intervention type: DRUG
Intervention: neoadjuvant therapy
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
Study: NCT02333630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AsthmaCare mobile health application
Description: Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education
Description: A website with links to written asthma education and videos
Study: NCT04417270

Intervention type: DEVICE
Group type: OTHER
Intervention: Freestyle Libre 14 day CGM system
Description: The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Freestyle Libre 14 day CGM system
Description: The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Accuchek Inform II platform
Description: The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.

Intervention type: DEVICE
Group type: OTHER
Intervention: Accuchek Inform II platform
Description: The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
Study: NCT02380742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine cream
Description: The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
Study: NCT02689349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Esteem
Description: Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of Esteem
Description: Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
Study: NCT00324506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (CellCept)
Study: NCT02833350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Study: NCT04471467

Intervention type: PROCEDURE
Intervention: Fixed tracheal tube
Description: Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
Study: NCT00719017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper vaginectomy
Description: Laparoscopic surgery with upper vaginectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative brachytherapy
Description: Laparoscopic surgery followed by brachytherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard procedures
Description: Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
Study: NCT03675139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate
Description: At a dosage of 10mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG
Description: At a dosage of 20 mg/day
Study: NCT05122312

Intervention type: DRUG
Group type: OTHER
Intervention: Olinanoseal
Description: it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.

Intervention type: DRUG
Group type: OTHER
Intervention: Olinanoseal
Description: it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.

Intervention type: DRUG
Group type: OTHER
Intervention: Curodont D'senz
Description: This agent contains p 11-4 peptide in addition to fluoride

Intervention type: DRUG
Group type: OTHER
Intervention: Curodont D'senz
Description: This agent contains p 11-4 peptide in addition to fluoride
Study: NCT00530335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
Study: NCT03213405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV 1/100
Description: 5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV 1/10
Description: 5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV full dose
Description: 1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional BCG full dose
Description: 2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.